# REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

> **NCT03460548** · NA · TERMINATED · sponsor: **TRB Chemedica** · enrollment: 26 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DEVICE:** Remogen
- **DEVICE:** Cationorm

## Key facts

- **NCT ID:** NCT03460548
- **Lead sponsor:** TRB Chemedica
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-30
- **Primary completion:** 2019-04-16
- **Final completion:** 2019-06-12
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** low recruitment rate
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03460548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03460548, "REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03460548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*